Vendor, Worcester, MA
Microbiotix, Inc.
UEI SCNKBDM341T1, CAGE 465F8
3 awards and $11,914,250 obligated between March 1, 2024 and August 26, 2026, 100% under full and open competition, against 38.0 offers on average where reported.
Sells to
Awarding agencies by dollars.
| National Institutes of Health | $11,954,346 |
| Defense Contract Management Agency | -$40,096 |
Industries
NAICS on the awards, by dollars.
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 3 |
| Definitive Contract | 3 |
Hear when Microbiotix, Inc. wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
Contracts Microbiotix, Inc. holds whose performance ends in the next 19 months, by published end date. Each one is a recompete to prepare for.
- Ending
- 1
- Obligated so far
- $6,726,374
- Soonest
- March 1, 2028
The 1 contract, the office behind each one and the dates are in the workspace. See them
Competes with
Vendors selling research and development in the physical, engineering, and life sciences (except nanotechnology and biotechnology) to National Institutes of Health, by dollars.
| Leidos Biomedical Research Inc.Frederick, MD | $2,186,369,442 |
| Westat, Inc.Rockville, MD | $760,724,225 |
| Technical Resources International, Inc.Bethesda, MD | $196,391,189 |
| Duke UniversityDurham, NC | $158,758,507 |
| MriglobalKansas City, MO | $117,921,746 |
| The Johns Hopkins UniversityBaltimore, MD | $100,932,043 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93023C00001Definitive Contract, October 10, 2024, Full and Open Competition, 10 offers | National Institutes of Health NiaidNational Institutes of Health | To Develop the PPZ Series of Small Molecule Pan-Filovirus Entry Inhibitors Through Lead Optimization, Selection of a Preclinical Candidate, NAICS 541715, PSC AN12 | $6,726,374 |
| 75N93020C00019Definitive Contract, March 1, 2024, Full and Open Competition, 12 offers | National Institutes of Health NiaidNational Institutes of Health | To Develop Phenoxyacetamide T3SS Inhibitors as Adjunctive Agents to Antibacterial Therapy for MDR P. Aeruginosa Infections.NAICS 541715, PSC AN12 | $5,227,972 |
| HDTRA118C0001Definitive Contract, December 4, 2024, Full and Open Competition, 92 offers | DCMA NortheastDefense Contract Management Agency | Develop Novel and Innovative Small Molecule Therapeutics to Treat (Post-Exposure Therapeutic) Infections by Both Filovirus Family Members (ENAICS 541714, PSC AD92 | -$40,096 |
- Places of performance
- Massachusetts
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied ResearchAD92
- Transactions
- 12 across 3 awards